Purpose. Macrolide susceptibility differs between subspecies in the Mycobacterium abscessus complex, likely due to differences in erm(41) sequevars. Patients with M. abscessus complex infection generally show poor clinical outcomes in response to antibiotic treatment. Here, the association between genotype and treatment outcome was investigated.
INTRODUCTION
Mycobacterium abscessus is an emerging pathogen that is responsible for a wide spectrum of diseases, including respiratory infections, particularly in patients with chronic lung disease or skin, soft tissue and bone infections. Further, this bacterium is known to cause rare disseminated disease in patients with severely immunosuppressed non-cystic fibrosis (CF) [1] . The M. abscessus complex was recently divided into three subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense and M. abscessus subsp.
bolletii [2, 3] . Macrolides are key drugs in the treatment of diseases caused by M. abscessus complex [1, 4, 5] . However, macrolide susceptibility varies among subspecies [6] [7] [8] and is primarily mediated by the inducible expression of an erythromycin ribosomal methylase gene, erm(41) [9] . Both M. bolletii and M. abscessus subsp. abscessus harbour intact erm(41) genes; however, a T/C polymorphism at position 28 in the chromosome of M. abscessus subsp. abscessus results in clarithromycin-inducible resistance (T28) or phenotypic susceptibility (C28) [10] . M. abscessus subsp. massiliense harbours a dysfunctional erm(41) gene as a result of the deletion of nucleotides 64-65 and 159-432, leading to a macrolide-susceptible phenotype [9] . According to recent reports, erm(41) sequence variants in M. abscessus subsp. abscessus are associated with differences in clarithromycin susceptibility [11] [12] [13] . In addition, acquired macrolide resistance [minimum inhibitory concentration (MIC) greater than 8 mg l
À1
] results from point mutations at positions 2057-2059 in the 23S rRNA gene (rrl) [14, 15] . Based on these observations, testing for genetic mechanisms and susceptibility is required in cases of treatment failure [16, 17] . However, in a recent report, recurrence in patients with lung disease caused by M. abscessus subsp. massiliense was due to reinfection with a strain that was indistinguishable from that isolated prior to treatment. Thus, although treatment failure is attributed to resistance selection, it may also be related to particular DNA polymorphisms within the complex, or strain variation [18] .
In the present study, the molecular mechanisms underlying clarithromycin resistance were characterized in a collection of M. abscessus complex isolates, and polyclonal infections were detected. In addition, we analysed erm(41) sequence variants and variable-number tandem repeats (VNTR) in the M. abscessus complex to assess their individual roles in phenotypic resistance.
METHODS Ethics
All study procedures were approved by the Ethics Committee of Kinki-chuo Chest Medical Center (no. 502) and were performed in accordance with the Declaration of Helsinki. Since this retrospective observational study was performed using the opt-out method through our hospital website, informed consent was not obtained from the patients.
Study population
According to our medical records, 35 patients with non-CF bronchiectasis visited the National Hospital Organization Kinki-chuo Chest Medical Center (Sakai-shi, Osaka, Japan) between 1 January 2008 and 30 September 2016. Twentyfour patients were diagnosed with M. abscessus complex lung disease based on the diagnostic guidelines published by the American Thoracic Society/Infectious Diseases Society of America [1] . The remaining 11 patients, who did not meet the diagnostic criteria, were referred to as colonized patients. Patients co-infected with other nontuberculous mycobacterial (NTM) species during the study were excluded from the study population. During routine laboratory testing, a total of 69 M. abscessus complex isolates were collected from 35 patients. The single isolates from 11 colonized patients were included in the phenotypic and genotypic analyses for comparison, but were excluded from the outcome analysis.
Treatment outcome
Patients underwent long-term therapy, administered every 3-6 months, in cases of significant radiographic progression or worsening respiratory symptoms. Patients who could not expectorate sputum after three consecutive negative cultures from sputum specimens were classified as having sustained culture conversion. Final treatment outcomes were classified as either sustained culture conversion with improvement of clinical symptoms and radiographic deterioration (favourable) or treatment failure (unfavourable). Patients with chronic disease who were classified as exhibiting culture conversion without antibiotic treatment were regarded as followed-up [8, 19] . Treatment failure included a lack of culture conversion with progressive radiographic abnormalities and clinical deterioration (progressive) or recurrence after the initial culture conversion (recurrence). Microbiological recurrence was defined by two or more positive culture results after the completion of treatment. Twenty-one patients, excluding 3 followed-up and 11 colonized patients, received combination antibiotic therapy consisting of the following oral macrolides: clarithromycin (800 mg day ), and at least two parenteral antibiotics, such as amikacin (400 mg day -1 ) and imipenem (1500 mg day -1 ).
Microbiological examination
Acid-fast bacilli (AFB) smears and mycobacterial cultures were performed as recommended in standard guidelines [1] . Sixty-nine isolates from 35 patients were cultured using the Bactec MGIT 960 system (Becton Dickenson, Fukushima, Japan) or Ogawa KY solid medium (Kyokuto Pharmaceutical Industrial Co., Tokyo, Japan), and subspecies were identified based on rpoB and hsp65 sequencing, as described previously [18] . Drug susceptibility testing was performed by the broth microdilution method using cation-adjusted Mueller-Hinton broth (CA-MH broth; Kyokuto Pharmaceutical Industrial Co.) [20] . The MIC was defined as the lowest drug concentration at which no visual growth was observed. Clarithromycin resistance and susceptibility were defined as MICs of >8 and <2 mg l À1 , respectively. Inducible resistance was defined as MICs of <8 and !8 mg l À1 at days 3 and 14, respectively. To investigate the distribution of amikacin-, imipenem-and sitafloxacin-resistant isolates, susceptibility was examined for each drug. The MICs of these antibiotics were determined at 3 days after cultivation. However, we could not obtain data for other quinolones (moxifloxacin or levofloxacin), azithromycin, or antimycobacterial agents (rifampicin and ethambutol) owing to financial constraints. erm(41) and rrl sequencing Extracted DNA was suspended in 0.3 ml of Tris-EDTA buffer and boiled for 10 min. The erm(41) gene was amplified using the forward primer ermF (5¢-GACCGGGGCC TTCTTCGTGAT-3¢) and the reverse primer ermR1 (5¢-GACTTCCCCGCACCGA-TTCC-3¢) [16, 21] . Gene variants were identified based on sequencing results [11] [12] [13] . The determined erm(41) sequences of M. massiliense (accession nos FJ358487 to FJ358490), M. bolletii (accession no. FJ358491) and M. abscessus (accession nos FJ358483 to FJ358486) were deposited in GenBank. Sequencing of the 23 rRNA gene (rrl) was performed as described by Rubio et al. [15] . The rrl gene was amplified using primers 19F (5¢-G TAGCGAAATTCCTTGTCGG-3¢) and 21R (5¢-TTCCCGC TTAGATGCTTTCAG-3¢) [15] . The PCR cycle conditions for both analyses were as follows: 5 min at 95 C, followed by 35 cycles of 95 C for 60 s, 62 C for 60 s and 72 C for 90 s, with a final extension at 72 C for 10 min.
VNTR genotyping and susceptibility analysis Mycobacterial genotyping was performed by VNTR analyses of initial and serial isolates [22] . The tandem repeat (TR) 28 locus was excluded from our analysis as a stable size difference between M. abscessus subsp. abscessus and M. abscessus subsp. massiliense isolates was not detected [23] . Between initial and serial isolates, we categorized infections as mixed-strain infections (when more than one allele was identified at more than one locus) and clonalvariant-population infections (when more than one allele was identified at a single locus) [24] . To determine susceptibility, DNA sequencing and VNTR analyses were repeated three times to confirm the results; the sequences and VNTRs were subsequently compared with those of M. abscessus JCM13569T, M. massiliense JCM15300T and M. bolletii JCM15297T as reference sequences, using phenotypic and genotypic antibiograms. 
RESULTS

Characteristics of patients
Treatment outcomes
In the 24 patients, the sequences of erm(41) and rrl were compared between 18 patients with unfavourable responses (14 M. abscessus subsp. abscessus and 4 M. abscessus subsp. massiliense, progressive or recurrent disease) and 6 patients with favourable responses (Tables 1 and 2 ). As expected, isolates from patients with unfavourable outcomes tended to exhibit clarithromycin resistance at day 3 (6/18, 33.3 vs 0/6, 0 %), mixed sequevars (7/18, 38.9 vs 1/6, 16.7 %) and different VNTR profiles (6/18, 33.3 vs 1/6, 16.7 %). In addition, the erm(41) C28 sequevar (5/7, 71.4 %) was more prevalent in M. abscessus subsp. abscessus from the 11 colonized patients than from those showing unfavourable outcomes (2/14, 14.3 %) or favourable outcomes (0/3, 0 %).
M. abscessus subsp. abscessus in patients with unfavourable outcomes appeared more resistant to clarithromycin than pathogens isolated from patients with favourable outcomes, although the distribution of resistance against amikacin, imipenem, or sitafloxacin was similar among the groups, i.e. favourable outcome, unfavourable outcome and colonization groups (Table 2) .
Clarithromycin susceptibility testing
The phenotypic susceptibility data for the 69 isolates are summarized in Table S1 (available in the online version of this article). Notably, 7 of the 47 M. abscessus subsp. abscessus isolates were clarithromycin-resistant on day 3. Of the 40 isolates that showed initial sensitivity, 9 were susceptible by day 14, whereas the remaining 31 displayed inducible resistance. In contrast, of the 22 M. abscessus subsp. massiliense isolates, 6 were resistant and 16 were susceptible at either day 3 or day 14.
erm(41) polymorphisms
The 69 isolates lacked variation in rpoB and hsp65, which is used for species identification. Based on an erm (41) T/C 28 polymorphism analysis of the 47 M. abscessus subsp. abscessus isolates, 38 T28-type strains were identified in patients with complex-related disease and two were identified in colonized patients, whereas four C28 strains were isolated from two patients with complexrelated disease and five with colonization. We also identified erm(41) polymorphisms in 22 M. abscessus subsp. 
Total (n=35, 69) 12 (32) 6 (13) 3 (6) 3 (7) 11 (11) *Colonized patients (seven M. abscessus and four M. massiliesne) were excluded from comparisons of subspecies with respect to treatment outcomes.
massiliense isolates with a dinucleotide deletion at position 64-65 and a 273 bp truncation, including 18 isolates in 7 patients and 4 isolates from 4 colonized patients, respectively. Discrepancies were observed in four isolates from patient Mm02; these isolates were subsequently determined to be a mixture of M. abscessus subsp. abscessus and M. abscessus subsp. massiliense (Fig. S1 ).
erm(41) sequevars
In this study, 12 sequevars were identified, each comprising a single isolate, including 1 unique and 8 previously published sequevars. The remaining were mixtures of sequevars identified in 10 isolates (01 and 06, 01 and 07, 06 and truncated). Differences were observed in the sequevars between the initial and post-treatment isolates in seven patients (Tables 3 and 4) . Four isolates belonged to sequevar 02 (containing a T28C mutation) and exhibited susceptibility at day 14 (Table 3) . However, we did not find any isolates harbouring the erm(41) T19 variant. (Table 3) .
Among the seven patients with M. abscessus subsp. massiliense, six isolates from two patients (Mm01 and Mm02) in the progression and recurrence groups displayed resistance. VNTRs of TR45, TR109, TR116, TR150, TR155, TR172, TR86, TR200, TR139, TR167, TR179, TR163, TR101, TR149, TR131,  TR2 , and TR137. §GTGACGGGGCTAT in SNPs of the erm(41) sequevar.
Susceptibility testing and rrl sequencing were concordant for mutations at positions 2057 or 2059. Furthermore, the initial and serial isolates from Mm02 showed an acquired mutation at these positions during treatment (Table 4) . 
Differentiation between clinical isolates by VNTR
DISCUSSION
Clarithromycin-resistant M. abscessus complex isolates were identified, and the mechanisms underlying resistance were examined. The relationship between inducible macrolide resistance and treatment outcomes with macrolide-based regimens has been examined in several recent reports [8, 9, 23] . The culture conversion rate in patients with pulmonary M. abscessus subsp. massiliense disease was higher than that in patients with M. abscessus subsp. abscessus [6, 25] . However, acquired mutational resistance may occur post-therapy [14] . In a recent study, progression rates were similar, despite significantly different treatment outcomes, in VNTRs of TR45, TR109, TR116, TR150, TR155, TR172, TR86, TR200, TR139, TR167, TR179, TR163, TR101, TR149, TR131,  TR2, and TR137. patients with lung disease caused by M. abscessus subsp. abscessus and M. abscessus subsp. massiliense [26] . We identified M. abscessus isolates with rrl point mutations and erm (41) sequevar variations. The development of clarithromycin resistance from susceptible M. abscessus subsp. abscessus and M. abscessus subsp. massiliense isolates was associated with unfavourable treatment outcomes [15, 27] . Interestingly, three patients (16.7 %) acquired clarithromycin resistance with persistent or recurrent positive cultures during treatment, and this was consistent with previously reported rates (13 %) [8] .
Acquired macrolide resistance by NTM, including in the M. abscessus complex, is infrequent after multidrug longterm therapy [8, 28] . In the present study, one patient (Mm01), who failed to produce a negative sputum culture, was infected with macrolide-susceptible M. abscessus subsp. massiliense during long-term treatment; however, subsequent isolates showed high resistance (>64 mg l
À1
) and a mutation in rrl. We found that the initial and serial isolates were indistinguishable using VNTRs. A previous report demonstrated that patients with M. abscessus subsp. massiliense treated with a regimen including macrolide-containing antibiotics develop clarithromycin resistance upon recurrence of infection [27] . The results of our study were consistent with these previous findings, suggesting that episodes of infection during or after treatment typically result from reinfection with same strain.
The mechanism by which clarithromycin resistance is acquired during macrolide-containing antibiotic treatment has not been fully elucidated. In our study, one patient (Mab13) was reinfected with a highly resistant strain carrying wild-type rrl. Wild-type strains are typically susceptible to conventional antibiotics. However, low-level resistance may be subject to constitutive efflux pump activation early in the treatment period, which is thought to be the first step in acquiring mutational resistance [27, 29] . Although no low-level clarithromycin-resistant isolates (8 mg l À1 ) were observed in our study, strains with intermediate resistance (4 mg l À1 ) were found to harbour wild-type rrl. Thus, the mechanisms underlying acquired macrolide resistance remain unclear. Furthermore, the observation of the coexistence of wild-type and mutant strains in initial isolates (Mab02 and Mab03) is important, as it indicated that acquired resistance during treatment is difficult to detect using susceptibility testing.
A recent report recommended a 7-day incubation procedure to assess antibiotic resistance [12] . In contrast, Brown-Elliot et al. [11] suggested that interpretation after extended incubation was difficult for rapidly growing mycobacteria, as poor growth may lead to false-positive susceptibility results. Furthermore, treated isolates tend to exhibit suboptimal growth in CA-MH broth [11] . As poor growth was observed in some serial isolates in the present study, the interpretation of MICs in our study was consistent with the Clinical and Laboratory Standards Institute (CLSI) guidelines [20] at day 14.
Our analyses revealed a discrepancy in isolates from patient Mm02, which were originally identified as M. abscessus subsp. massiliense, but were later revealed to be mixed sequevars by erm(41) gene sequencing. This is the first study to identify an association between mixed sequevars and unfavourable treatment outcomes. Several cases of M. abscessus subsp. massiliense with a functional erm(41) gene have been reported [15, 16] . Thus, our data supported the development of erm(41) gene transfer methods and the investigation of fluctuations in recombinant strains during treatment.
Interestingly, we also found two mixed genetic populations: the acquisition of a point mutation at position 2057 and the wild-type genotype from two patients with progressive M. abscessus subsp. abscessus disease, and double mutations at positions 2057 and 2058 (Mab05), or positions 2057 and 2059 (Mm02). Further, erm(41) sequevar analysis indicated that six isolates (24 %) comprised sequevars 01 and 06, which were prevalent in patients with persistent disease. An isolate consisting of sequevar 06 and M. abscessus subsp. massiliense with truncated erm(41) was found in patient Mm02 with progressive disease (Fig. S1 ). Interesting results were also observed by VNTR analysis, which showed double or triple bands in the initial isolates and an absence of PCR products in serial isolates. The VNTR patterns with multiple bands appeared to minimize the potential for technical errors by mis-scoring; the clonal stability of each of the 17 VNTR loci has been evaluated in previous reports [22, 23] . In patient Mab04, two different TR 2 alleles (four and six repeats) were simultaneously observed in the initial isolate, whereas only six repeats were observed in a sample collected 11 months post-treatment (Table 2) . Patient Mab06, with progressive disease, displayed similar findings, with triple peaks in TR86, and double peaks in TR163 for 24 months. Thus, these data suggest that isolates from patients showing unfavourable response contain clonal variants that differ from the parent strain. Furthermore, we found that two patients (Mab08 and Mm04) were infected with polyclonal populations, based on genetic VNTR profiles. Thus, patients infected with NTM species, including the M. abscessus complex, who have undergone unsuccessful treatment are at risk of repeated or multiple infections [14] . Indeed, a recent study suggested that the average patient with pulmonary M. avium complex or M. abscessus subsp. abscessus disease exhibited polyclonal infections [8, 27, 29, 30] . In contrast, VNTR profiles and repetitive element sequence-based PCR (rep-PCR) clusters strongly suggested that patients with CF in the UK were persistently infected with a single strain [18] . According to another study, strains from patients in Spain were identical to the initial isolates [15] . However, CF is relatively rare in the Japanese population; therefore, further analyses with samples obtained from different geographical regions are needed to investigate the risk of polyclonal infection in these patients.
In this study, erm(41) gene sequencing was used to classify M. abscessus subsp. abscessus isolates into sequevars based on 13 single nucleotide polymorphisms, of which only dysfunctional sequevar 02 (T28C) with full-length erm(41) was associated with susceptibility. Interestingly, M. abscessus subsp. massiliense and sequevar 2 had higher frequencies than the other sequevars in colonized subjects (Table 2) . It is still unclear whether colonization results from M. abscessus subsp. massiliense strains with decreased virulence or non-functional erm(41). Nevertheless, subspecies identification and erm(41) sequencing could help to predict treatment outcomes for M. abscessus complex lung disease. Previous reports have indicated that M. abscessus subsp. massiliense is highly transmissible between patients with CF [16, 31] . Accordingly, if M. abscessus subsp. abscessus sequevar 02 and M. abscessus subsp. massiliense are more transmissible, erm(41) sequevar analyses may be an effective method for controlling infection.
The present study had several limitations. Most importantly, it was a single-institution study with a limited patient population. In addition, we were unable to compare a sufficient number of favourable outcomes for M. abscessus subsp. massiliense lung disease, as the duration of treatment and follow-up were short, which may have resulted in underestimation of favourable outcome rates. We were unable to verify the roles of complex factors contributing to success or failure in the present patients; these may include pharmacological factors such as relationships between drug concentration profiles and pharmacological effects, and non-pharmacological factors such as treatment by chest physiotherapy. Finally, the isolates were only analysed genetically, and no morphological information was collected; thus, we could not determine whether a particular strain was associated with persistent infection.
In conclusion, our data indicated that several patients were infected with polyclonal populations based on genetic VNTR profiles and erm(41) sequevars. Genetic analysis suggested that some cases of persistent or recurrent disease resulted from acquired resistance or reinfection. The coexistence of DNA polymorphisms involved in macrolide resistance and erm(41) sequevars suggested that individual patients were persistently infected with different strains harbouring key genetic mutations. Therefore, novel methods to determine the specific strains responsible for repeated infections and develop effective measures to reduce patient exposure to pathogens that are difficult to treat are urgently needed.
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